Challenges to sovereign ambitions: Forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union

Research output: Contribution to journalArticlepeer-review

Abstract

This paper maps key regulatory, governance and legal challenges associated with the UK's withdrawal from the European Union (EU) in terms of convergent and divergent pressures within the global pharmaceutical sector. These include (i) convergent regulatory pressures associated with the European framework for pre-market licensing; (ii) convergent and divergent industry pressures with regard to drug discovery and manufacturing; and (iii) divergent and convergent market pressures associated with the supply, pricing and assessment of medicines. The UK's sovereign ambitions risk a loss of influence over the licensing and surveillance of pharmaceuticals under convergent regulatory and industry pressures to engage in unilateral participation in the European regime. Further, they also risk a loss of influence over processes for pricing and assessing the effectiveness of new treatment regimens under divergent market pressures from larger pharmaceutical markets outside the EU, notably the United States.

Bibliographical metadata

Original languageEnglish
Pages (from-to)1-17
Number of pages17
JournalHealth Economics, Policy and Law
Volume15
DOIs
Publication statusPublished - 25 Jun 2020

Related information

Researchers

View all